Intelgenx Technologies Stock Price, News & Analysis (CVE:IGX)

C$0.97 -0.02 (-2.02 %)
(As of 02/22/2018 04:00 PM ET)
Previous CloseC$0.99
Today's RangeC$0.97 - C$1.04
52-Week RangeC$0.78 - C$1.39
Volume1,800 shs
Average Volume13,265 shs
Market CapitalizationC$62.34 million
P/E Ratio-33.00
Dividend YieldN/A

About Intelgenx Technologies (CVE:IGX)

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company’s products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimer’s disease. It is also developing various products, including INT0037/2013, INT0039/2013, INT0040/2014, INT0041/2015, INT0042/2015, and INT0044/2016 based on three delivery platform technologies, which consist of VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology; and AdVersa, a mucoadhesive tablet technology. The company has co-development and commercialization agreements with RedHill Biopharma Ltd.; Par Pharmaceutical Companies, Inc.; and Endo Ventures Ltd., as well as a licensing, development, and supply agreement with Chemo Group. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Saint-Laurent, Canada.

Receive IGX News and Ratings via Email

Sign-up to receive the latest news and ratings for IGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-33
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares66,931,000

Intelgenx Technologies (CVE:IGX) Frequently Asked Questions

What is Intelgenx Technologies' stock symbol?

Intelgenx Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IGX."

When will Intelgenx Technologies make its next earnings announcement?

Intelgenx Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, March, 27th 2018. View Earnings Estimates for Intelgenx Technologies.

Who are some of Intelgenx Technologies' key competitors?

How do I buy Intelgenx Technologies stock?

Shares of Intelgenx Technologies and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Intelgenx Technologies' stock price today?

One share of Intelgenx Technologies stock can currently be purchased for approximately C$0.97.

How big of a company is Intelgenx Technologies?

Intelgenx Technologies has a market capitalization of C$62.34 million.

MarketBeat Community Rating for Intelgenx Technologies (IGX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  8 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  15
MarketBeat's community ratings are surveys of what our community members think about Intelgenx Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intelgenx Technologies (CVE:IGX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyN/AN/AN/A
Consensus Rating Score: 3.00N/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Intelgenx Technologies (CVE:IGX) Consensus Price Target History

Price Target History for Intelgenx Technologies (CVE:IGX)

Intelgenx Technologies (CVE:IGX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
1/29/2018AegisReiterated RatingBuyView Rating Details
(Data available from 2/22/2016 forward)


Intelgenx Technologies (CVE:IGX) Earnings History and Estimates Chart

Earnings by Quarter for Intelgenx Technologies (CVE:IGX)

Intelgenx Technologies (CVE IGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017C($0.01)C($0.01)ViewN/AView Earnings Details
8/10/2017Q2 2017C($0.01)C($0.01)ViewN/AView Earnings Details
5/11/2017Q1 2017C($0.01)ViewN/AView Earnings Details
8/11/2016Q2 2016C($0.02)ViewN/AView Earnings Details
5/10/2016Q1 2016C($0.02)ViewN/AView Earnings Details
3/30/2016Q4 2015C$0.01ViewN/AView Earnings Details
11/3/2015Q3 2015C$0.03ViewN/AView Earnings Details
11/12/2014Q3 2014C($0.01)ViewN/AView Earnings Details
8/7/2014Q2 2014C($0.01)ViewN/AView Earnings Details
5/13/2014Q1 2014C($0.01)ViewN/AView Earnings Details
3/11/2014Q4 2013C($0.01)ViewN/AView Earnings Details
11/8/2013Q3 2013C($0.01)ViewN/AView Earnings Details
5/14/2013Q1 2013C($0.01)ViewN/AView Earnings Details
3/18/2013Q4 2012C($0.01)ViewN/AView Earnings Details
11/13/2012Q3 2012C($0.01)ViewN/AView Earnings Details
8/7/2012Q2 2012C($0.01)ViewN/AView Earnings Details
5/15/2012Q1 2012C($0.01)ViewN/AView Earnings Details
3/29/2012Q4 2011C($0.01)ViewN/AView Earnings Details
11/9/2011Q3 2011C($0.01)ViewN/AView Earnings Details
8/9/2011Q2 2011C($0.01)ViewN/AView Earnings Details
5/11/2011Q1 2011C($0.01)ViewN/AView Earnings Details
3/30/2011Q4 2010C($0.02)ViewN/AView Earnings Details
8/12/2010Q2 2010C($0.03)ViewN/AView Earnings Details
5/14/2010Q1 2010C($0.02)ViewN/AView Earnings Details
3/31/2010Q4 2009C($0.01)ViewN/AView Earnings Details
11/10/2009Q3 2009C($0.03)ViewN/AView Earnings Details
5/13/2009Q1 2009C($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Intelgenx Technologies (CVE:IGX) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Intelgenx Technologies (CVE:IGX)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Intelgenx Technologies (CVE IGX)

No insider trades for this company have been tracked by


Intelgenx Technologies (CVE IGX) News Headlines

Intelgenx Technologies (IGX) Given "Buy" Rating at AegisIntelgenx Technologies (IGX) Given "Buy" Rating at Aegis - February 1 at 6:52 AM
IntelGenx Mourns the Passing of long term Director Ian Troup - GlobeNewswire (press release)IntelGenx Mourns the Passing of long term Director Ian Troup - GlobeNewswire (press release) - January 27 at 8:09 AM
IntelGenx Submits Montelukast VersaFilm Clinical Trial Application With Health CanadaIntelGenx Submits Montelukast VersaFilm Clinical Trial Application With Health Canada - November 11 at 11:41 AM
Intelgenx Technologies Corp. (IGX) to Release Earnings on ThursdayIntelgenx Technologies Corp. (IGX) to Release Earnings on Thursday - November 3 at 10:58 AM
IntelGenX Technologies Corp. (IGX) Scheduled to Post Earnings on ThursdayIntelGenX Technologies Corp. (IGX) Scheduled to Post Earnings on Thursday - August 4 at 3:32 PM

SEC Filings

Intelgenx Technologies (CVE:IGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Intelgenx Technologies (CVE IGX) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.